FindTrial
Sign In

Immune checkpoint inhibitor versus chemotherapy for elderly non-small cell lung cancer:a meta-analysis

Immune checkpoint inhibitor versus chemotherapy for elderly non-small cell lung cancer:a meta-analysis - ICI for elderly NSCLC

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000036706
Enrollment
1000
Registered
2019-05-13
Start date
2019-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Sponsors

Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with non-small cell lung cancer aged 65 years or older

Exclusion criteria

Exclusion criteria: patients with non-small cell lung cancer aged less than 65 years.

Design outcomes

Primary

MeasureTime frame
Overall survival(OS)—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University School of Medicine Department of Medicine, Division of Respiratory Medicine and Allergology

koichi-a@med.showa-u.ac.jp+81-3-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026